Persistent Epstein-Barr viral load in Epstein-Barr viral naïve pediatric heart transplant recipients: Risk of late-onset post-transplant lymphoproliferative disease

Table 1 Outcomes (post-transplant lymphoproliferative disorder and number of rejections) by Epstein-Barr virus serological status at heart transplant

	Group I (EBV PCR negative or < 1000) (n = 66)	Group II (EBV PCR 1000-9999) (n = 47)	Group III (EBV PCR≥10000) (n = 32)
EBV Naïve at HT	29/66 (44%)	13/47 (28%)	12/32 (37%)
Age at transplant
0 up to < 6 mo	9	10	12
6 mo < 1 yr	3	5	3
1 yr up to < 7 yr	28	8	8
≥ 7 yr up to 20 yr	26	24	9
Post-HT Follow-up (yr)	4.5 ± 3.2	4.8 ± 4.2	4.6 ± 5.3
No of PTLD	1	3	4
No of total Rejections	40	42	48
Number of patients with ≥ 1 episodes of rejections	19	22	23

EBV: Epstein-Barr virus; PCR: Polymerase chain reaction; HT: Heart transplant; PTLD: Post-transplant lymphoproliferative disorder.